CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Alimera Sciences, Inc. - ALIM CFD

3.43
1.48%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.28
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 3.38
Open* 3.44
1-Year Change* 72%
Day's Range* 3.43 - 3.49
52 wk Range 1.30-4.38
Average Volume (10 days) 108.31K
Average Volume (3 months) 1.74M
Market Cap 203.90M
P/E Ratio -100.00K
Shares Outstanding 52.42M
Revenue 68.48M
EPS -2.63
Dividend (Yield %) N/A
Beta 1.21
Next Earnings Date Mar 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 3.43 -0.01 -0.29% 3.44 3.52 3.41
Apr 15, 2024 3.38 0.13 4.00% 3.25 3.48 3.25
Apr 12, 2024 3.40 -0.19 -5.29% 3.59 3.65 3.31
Apr 11, 2024 3.69 0.07 1.93% 3.62 3.72 3.62
Apr 10, 2024 3.61 -0.04 -1.10% 3.65 3.65 3.48
Apr 9, 2024 3.65 -0.01 -0.27% 3.66 3.67 3.58
Apr 8, 2024 3.64 -0.02 -0.55% 3.66 3.74 3.57
Apr 5, 2024 3.71 -0.02 -0.54% 3.73 3.78 3.58
Apr 4, 2024 3.76 -0.08 -2.08% 3.84 3.84 3.72
Apr 3, 2024 3.82 0.10 2.69% 3.72 3.82 3.67
Apr 2, 2024 3.76 0.09 2.45% 3.67 3.76 3.58
Apr 1, 2024 3.70 0.05 1.37% 3.65 3.76 3.62
Mar 28, 2024 3.76 0.11 3.01% 3.65 3.82 3.62
Mar 27, 2024 3.73 -0.02 -0.53% 3.75 3.77 3.63
Mar 26, 2024 3.70 -0.03 -0.80% 3.73 3.85 3.60
Mar 25, 2024 3.84 -0.12 -3.03% 3.96 4.01 3.80
Mar 22, 2024 3.80 0.09 2.43% 3.71 3.80 3.71
Mar 21, 2024 3.85 0.25 6.94% 3.60 3.86 3.60
Mar 20, 2024 3.68 -0.08 -2.13% 3.76 3.81 3.59
Mar 19, 2024 3.88 0.01 0.26% 3.87 3.93 3.79

Alimera Sciences, Inc. Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Alimera Sciences Inc Earnings Release
Q1 2024 Alimera Sciences Inc Earnings Release

Forecast

-

Previous

-
Wednesday, July 31, 2024

Time (UTC)

13:30

Country

US

Event

Alimera Sciences Inc Annual Shareholders Meeting
Alimera Sciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 54.129 59.029 50.82 53.943 46.599
Revenue 54.129 59.029 50.82 53.943 46.599
Cost of Revenue, Total 7.977 7.03 6.941 6.626 4.308
Gross Profit 46.152 51.999 43.879 47.317 42.291
Total Operating Expense 65.769 57.438 51.321 59.217 58.035
Selling/General/Admin. Expenses, Total 38.858 35.843 32.036 38.958 38.042
Research & Development 16.228 13.778 9.668 10.992 11.274
Depreciation / Amortization 2.706 2.579 2.676 2.641 2.645
Unusual Expense (Income) 0 -1.792 0 1.766
Operating Income -11.64 1.591 -0.501 -5.274 -11.436
Interest Income (Expense), Net Non-Operating -5.789 -4.997 -4.906 -4.953 -4.84
Net Income Before Taxes -18.079 -3.934 -5.407 -10.227 -16.276
Net Income After Taxes -18.107 -4.372 -5.339 -10.443 -16.382
Net Income Before Extra. Items -18.107 -4.372 -5.339 -10.443 -16.382
Net Income -18.107 -4.372 -5.339 -10.443 -16.382
Income Available to Common Excl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
Income Available to Common Incl. Extra. Items -18.107 -4.372 -5.339 -10.443 21.948
Diluted Net Income -18.107 -4.372 -5.339 -10.443 21.948
Diluted Weighted Average Shares 6.99685 6.59524 5.11766 4.7702 5.91587
Diluted EPS Excluding Extraordinary Items -2.58788 -0.6629 -1.04325 -2.18921 3.71002
Diluted Normalized EPS -2.58788 -0.83951 -1.04325 -2.18921 3.90406
Other Operating Expenses, Total
Total Extraordinary Items 0 0
Total Adjustments to Net Income 0 38.33
Other, Net -0.65 -0.528
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 17.538 13.546 14.029 13.598 14.604
Revenue 17.538 13.546 14.029 13.598 14.604
Cost of Revenue, Total 2.425 2.028 2.125 2.006 2.166
Gross Profit 15.113 11.518 11.904 11.592 12.438
Total Operating Expense 19.825 16.848 16.137 17.009 16.578
Selling/General/Admin. Expenses, Total 10.807 9.975 9.099 9.856 9.81
Research & Development 3.648 4.164 4.23 4.483 3.932
Depreciation / Amortization 1.866 0.681 0.683 0.664 0.67
Operating Income -2.287 -3.302 -2.108 -3.411 -1.974
Interest Income (Expense), Net Non-Operating -1.701 -1.68 -1.621 -1.567 -1.345
Net Income Before Taxes -10.004 -4.968 -3.781 -5.245 -3.098
Net Income After Taxes -10.029 -4.968 -3.78 -5.257 -3.115
Net Income Before Extra. Items -10.029 -4.968 -3.78 -5.257 -3.115
Net Income -10.029 -4.968 -3.78 -5.257 -3.115
Income Available to Common Excl. Extra. Items -10.698 -4.982 -3.78 -5.257 -3.115
Income Available to Common Incl. Extra. Items -10.698 -4.982 -3.78 -5.257 -3.115
Diluted Net Income -10.698 -4.982 -3.78 -5.257 -3.115
Diluted Weighted Average Shares 8.09364 7.03223 7.00032 6.99658 6.99971
Diluted EPS Excluding Extraordinary Items -1.32178 -0.70845 -0.53998 -0.75137 -0.44502
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.23512 -0.70845 -0.53998 -0.75137 -0.44502
Unusual Expense (Income) 1.079 0 0 0
Other, Net -6.016 0.014 -0.052 -0.267 0.221
Total Adjustments to Net Income -0.669 -0.014
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 29.413 42.16 34.906 32.745 34.848
Cash and Short Term Investments 5.274 16.51 11.208 9.426 13.043
Cash & Equivalents 5.274 16.51 11.208 9.426 13.043
Total Receivables, Net 19.612 19.128 17.2 19.331 17.259
Accounts Receivable - Trade, Net 19.612 19.128 17.2 19.331 17.259
Total Inventory 1.605 2.679 2.746 1.39 2.405
Prepaid Expenses 2.892 3.809 3.718 2.565 2.109
Other Current Assets, Total 0.03 0.034 0.034 0.033 0.032
Total Assets 42.602 58.52 50.855 50.309 54.108
Property/Plant/Equipment, Total - Net 3.92 4.493 2.358 2.047 1.355
Property/Plant/Equipment, Total - Gross 7.981 7.923 6.305 5.858 4.967
Accumulated Depreciation, Total -4.061 -3.43 -3.947 -3.881 -3.612
Intangibles, Net 8.957 10.897 12.838 14.783 16.723
Other Long Term Assets, Total 0.129 0.137 0.753 0.734 1.182
Total Current Liabilities 39.732 12.592 12.348 12.048 10.234
Accounts Payable 10.088 8.706 7.461 7.077 6.355
Accrued Expenses 3.998 3.617 3.197 4.716 3.643
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 25.646 0.269 1.69 0.255 0.236
Other Current Liabilities, Total
Total Liabilities 63.41 61.125 58.833 54.754 51.386
Total Long Term Debt 18.683 43.08 42.922 38.752 38.178
Long Term Debt 18.683 43.08 42.408 38.658 37.873
Capital Lease Obligations 0.514 0.094 0.305
Other Liabilities, Total 4.995 5.453 3.563 3.954 2.974
Total Equity -20.808 -2.605 -7.978 -4.445 2.722
Preferred Stock - Non Redeemable, Net 19.227 19.227 19.227 30.344 30.344
Common Stock 0.07 0.069 0.057 0.05 0.701
Additional Paid-In Capital 378.238 377.229 365.83 350.117 346.108
Retained Earnings (Accumulated Deficit) -415.388 -397.281 -392.539 -383.863 -373.42
Other Equity, Total -2.955 -1.849 -0.553 -1.093 -1.011
Total Liabilities & Shareholders’ Equity 42.602 58.52 50.855 50.309 54.108
Total Common Shares Outstanding 6.99551 6.93515 5.71937 4.96595 4.67193
Total Preferred Shares Outstanding 0.6 0.6 0.6 0.61015 0.61015
Long Term Investments 0.183 0.833
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 48.402 46.022 35.675 29.413 29.76
Cash and Short Term Investments 8.285 18.775 13.086 5.274 5.514
Cash & Equivalents 8.285 18.775 13.086 5.274 5.514
Total Receivables, Net 33.943 22.589 18.433 19.612 19.142
Accounts Receivable - Trade, Net 33.943 22.589 18.433 19.612 19.142
Total Inventory 1.76 1.055 1.215 1.605 1.786
Prepaid Expenses 4.383 3.571 2.91 2.892 3.29
Other Current Assets, Total 0.031 0.032 0.031 0.03 0.028
Total Assets 154.192 154.923 48.239 42.602 43.429
Property/Plant/Equipment, Total - Net 3.618 3.742 3.757 3.92 3.87
Intangibles, Net 101.975 104.935 8.479 8.957 9.446
Other Long Term Assets, Total 0.127 0.131 0.131 0.129 0.118
Total Current Liabilities 17.721 14.245 14.173 39.732 34.01
Accounts Payable 6.205 8.04 9.669 10.088 8.706
Accrued Expenses 11.323 6.002 4.241 3.998 3.661
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.193 0.203 0.263 25.646 21.643
Total Liabilities 105.352 108.693 67.155 63.41 61.507
Total Long Term Debt 64.449 64.134 44.312 18.683 22.492
Long Term Debt 64.222 63.954 44.152 18.683 22.492
Capital Lease Obligations 0.227 0.18 0.16
Other Liabilities, Total 23.182 30.314 8.67 4.995 5.005
Total Equity 48.84 46.23 -18.916 -20.808 -18.078
Preferred Stock - Non Redeemable, Net 0 74.725 7.728 19.227 19.227
Common Stock 0.524 0.088 0.074 0.07 0.07
Additional Paid-In Capital 461.622 386.979 378.146 378.238 378.005
Retained Earnings (Accumulated Deficit) -410.312 -412.779 -402.081 -415.388 -411.608
Other Equity, Total -2.994 -2.783 -2.783 -2.955 -3.772
Total Liabilities & Shareholders’ Equity 154.192 154.923 48.239 42.602 43.429
Total Common Shares Outstanding 52.4168 8.80373 7.39159 6.99551 6.99802
Total Preferred Shares Outstanding 0 0.07862 0.012 0.6 0.6
Long Term Investments 0.07 0.093 0.197 0.183 0.235
Other Current Liabilities, Total
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -18.107 -4.372 -5.339 -10.443 -16.382
Cash From Operating Activities -9.975 -3.224 -2.193 -4.152 -11.553
Cash From Operating Activities 2.706 2.579 2.676 2.641 2.645
Deferred Taxes 0.116 0.61 0.031 0.454 -0.653
Non-Cash Items 2.621 -0.692 1.829 3.377 7.084
Cash Taxes Paid 0.232 0.112 0.11 0.239 0.239
Cash Interest Paid 4.489 4.302 4.556 4.419 3.571
Changes in Working Capital 2.689 -1.349 -1.39 -0.181 -4.247
Cash From Investing Activities -0.255 -0.621 -0.62 -0.174 -0.175
Capital Expenditures -0.255 -0.621 -0.62 -0.174 -0.175
Cash From Financing Activities -0.302 9.823 3.882 0.869 0.95
Financing Cash Flow Items -0.113 0 -0.019 -2.227 -3.808
Issuance (Retirement) of Stock, Net 0.1 10.044 0.049 0.902 0.085
Issuance (Retirement) of Debt, Net -0.289 -0.221 3.852 2.194 4.673
Foreign Exchange Effects -0.708 -0.676 0.714 -0.159 -0.248
Net Change in Cash -11.24 5.302 1.783 -3.616 -11.026
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.968 -18.107 -14.327 -9.07 -5.955
Cash From Operating Activities -2.209 -9.975 -9.724 -7.811 -6.213
Cash From Operating Activities 0.681 2.706 2.023 1.359 0.689
Non-Cash Items 0.507 2.621 2.095 1.318 1.027
Cash Taxes Paid 0 0.232 0.224 0.182 0.018
Cash Interest Paid 1.354 4.489 3.253 2.145 1.061
Changes in Working Capital 1.571 2.689 0.485 -1.418 -1.974
Cash From Investing Activities -0.009 -0.255 -0.171 -0.041 -0.149
Capital Expenditures -0.009 -0.255 -0.171 -0.041 -0.149
Cash From Financing Activities 9.998 -0.302 -0.109 -0.164 -0.062
Financing Cash Flow Items -3.123 -0.113
Issuance (Retirement) of Debt, Net 2.373 -0.289 -0.164 -0.204 -0.062
Foreign Exchange Effects 0.033 -0.708 -0.998 -0.638 -0.141
Net Change in Cash 7.813 -11.24 -11.002 -8.654 -6.565
Issuance (Retirement) of Stock, Net 10.748 0.1 0.055 0.04
Deferred Taxes 0.116

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alimera Sciences, Inc. Company profile

About Alimera Sciences Inc

Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Alimera Sciences Inc revenues increased 16% to $59M. Net loss decreased 18% to $4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects DEPRECIATION AND AMORTIZATION decrease of 4% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.66.

Equity composition

Common Stock $.01 Par, 05/11, 100M auth., 31,348,197 issd. IPO:TBA. Insider owns 2.06%.

Industry: Biopharmaceuticals

Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,746.70 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

63,533.20 Price
+0.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.50 Price
+0.870% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,391.05 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading